Sort

Search

01/07/2025 Proteomic analysis of Down syndrome cerebrospinal fluid compared to late-onset and autosomal dominant Alzheimers disease
Montoliu-Gaya, L, Bian, SJ, Dammer, EB, Alcolea, D, Sauer, M, Martá-Ariza, M, Ashton, NJ, Belbin, O, Fuchs, J, Watson, CM, Ping, LY, Duong, DM, Nilsson, J, Barroeta, I, Lantero-Rodriguez, J, Videla, L, Benejam, B, Roberts, BR, Blennow, K, Seyfried, NT, Levey, AI, Carmona-Iragui, M, Gobom, J, Lleó, A, Wisniewski, T, Zetterberg, H, Fortea, J, Johnson, ECB. Proteomic analysis of Down syndrome cerebrospinal fluid compared to late-onset and autosomal dominant Alzheimers disease. Nature Communications. 2025; 16(1)DOI:10.1038/s41467-025-61054-z. PMID:40595720. IF:15.700(Q1/1D).
01/07/2025 Medial temporal lobe atrophy in Down syndrome along the Alzheimer's disease continuum
Buehner, BJ, Morcillo-Nieto, AO, Zsadanyi, SE, Aranha, MR, Arriola-Infante, JE, Vaqué-Alcazar, L, Arranz, J, Rodríguez-Baz, I, Blesa, LM, Videla, L, Barroeta, I, Soriano, LD, Benejam, B, Fernández, S, Hernandez, AS, Bargalló, N, González-Ortiz, S, Giménez, S, de Flores, R, Yushkevich, PA, Alcolea, D, Belbin, O, Lleó, A, Carmona-Iragui, M, Fortea, J, Bejanin, A. Medial temporal lobe atrophy in Down syndrome along the Alzheimer's disease continuum. BRAIN. 2025; 148(7)DOI:10.1093/brain/awaf133. PMID:40243675. IF:11.700(Q1/1D).
01/07/2025 Clinical Features of Children With MOG-IgG Who Fulfill Criteria of Multiple Sclerosis and Overlapping Disorders
Fonseca, EG, Olivé-Cirera, G, Chen, LW, Paredes-Carmona, F, Enamorado, NN, Duran, SB, Mendibe, MD, Visa-Reñe, N, Vázquez-López, M, Felipe-Rucián, A, Romeu, G, Martinez-Hernandez, E, Blanco, Y, Sepulveda, M, Saiz, A, Dalmau, J, Armangue, T. Clinical Features of Children With MOG-IgG Who Fulfill Criteria of Multiple Sclerosis and Overlapping Disorders. Neurology-Neuroimmunology & Neuroinflammation. 2025; 12(4)DOI:10.1212/NXI.0000000000200400. PMID:40505071. IF:7.500(Q1/1D).
01/07/2025 Early safety after TAVR according to VARC-3 criteria: incidence, predictors, and clinical impact
Gonzálvez-García, A, Cepas-Guillén, P, Ternacle, J, Urena, M, Alperi, A, Cheema, AN, Veiga-Fernández, G, Nombela-Franco, L, Vilalta, V, Esposito, G, Campelo-Parada, F, Idolfi, C, del Trigo, M, Muñoz-García, A, Maneiro, N, Asmarats, L, Regueiro, A, del Val, D, Serra, V, Auffret, V, Jonveaux, M, Bonnet, G, Mesnier, J, Gaspard, S, Avanzas, P, Rezaei, E, Fradejas-Sastre, V, Tirado-Conte, G, Fernández-Nofrerías, E, Franzone, A, Guitteny, T, Sorrentino, S, Oteo, JF, Díez-Delhoyo, F, Gutiérrez-Alonso, L, Vidal, P, Alfonso, F, Monastyrski, A, Nolf, M, Pelletier-Beaumont, E, Avvedimento, M, Rodés-Cabau, J. Early safety after TAVR according to VARC-3 criteria: incidence, predictors, and clinical impact. REVISTA ESPANOLA DE CARDIOLOGIA. 2025; 78(7)DOI:10.1016/j.rec.2024.12.005. PMID:39722415. IF:4.900(Q1/2D).